Bcl2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| BCL2 Protein |
|---|
| Full Name | B-cell lymphoma 2 protein |
| Gene | BCL2 |
| UniProt ID | P10415 |
| PDB ID | 1GJH, 1G5M, 2O21, 4LHP |
| Molecular Weight | 26 kDa |
| Subcellular Localization | Mitochondrial outer membrane, ER membrane, Nuclear envelope |
| Protein Family | BCL2 family (anti-apoptotic) |
BCL2 (B-cell lymphoma 2) is the founding member of the BCL-2 family of proteins that regulate apoptosis. BCL2 is a critical anti-apoptotic protein that inhibits the mitochondrial pathway of cell death. It was first discovered as an oncogene in B-cell lymphomas, but is now recognized as a major neuroprotective protein.
BCL2 contains characteristic BCL-2 family domains:
- BH1 Domain: Forms the hydrophobic pocket for binding pro-apoptotic proteins
- BH2 Domain: Contributes to BH3 domain binding
- BH3 Domain: Critical for interaction with pro-apoptotic family members
- BH4 Domain: N-terminal domain important for anti-apoptotic function
- Transmembrane Domain: C-terminal anchor for mitochondrial membrane localization
BCL2 is the prototype anti-apoptotic BCL-2 family protein:
- Inhibition of MOMP: Directly binds and inhibits BAX and BAK, preventing mitochondrial outer membrane permeabilization
- Cytochrome c Sequestration: Prevents release of pro-apoptotic factors from mitochondria
- Anti-oxidant Function: Reduces ROS production and protects against oxidative damage
- Autophagy Regulation: Interacts with BECN1/Beclin-1 to regulate autophagy
- Calcium Homeostasis: Modulates ER calcium release
In neurons, BCL2 is essential for survival:
- Protects against excitotoxicity
- Maintains mitochondrial function
- Supports axonal integrity
- Pathology: Reduced BCL2 expression in AD brain; decreased BCL2/BAX ratio[1]
- Mechanism: Loss of neuroprotective function promotes amyloid-induced neuronal apoptosis
- Therapeutic Potential: BCL2 activators and BH3 mimetics being explored
- Pathology: BCL2 expression reduced in substantia nigra of PD patients[2]
- Mechanism: Dopaminergic neurons particularly vulnerable to BCL2 deficiency
- Therapeutic Potential: AAV-BCL2 gene therapy in development
- Pathology: Mutant huntingtin directly binds and inhibits BCL2[3]
- Mechanism: Loss of anti-apoptotic function in medium spiny neurons
- Pathology: BCL2 neuroprotective in ischemic injury
- Therapeutic Potential: BCL2 overexpression reduces infarct size
| Drug/Approach |
Description |
Status |
| Navitoclax (ABT-263) |
BH3 mimetic, BCL2 inhibitor |
Clinical trials (oncology) |
| Venetoclax (ABT-199) |
Selective BCL2 inhibitor |
Approved for leukemia |
| BCL2 Activators |
Direct activation of BCL2 |
Preclinical |
| AAV-BCL2 |
Gene therapy for neuroprotection |
Preclinical |
- [1] Manoohevari Z et al. (2020). "BCL2 and apoptosis in Alzheimer's disease." Journal of Molecular Neuroscience
- [2] Tatton WG et al. (2003). "Reduced BCL2 in Parkinson's disease." Experimental Neurology
- [3] Bae BI et al. (2006). "Mutant huntingtin interacts with BCL2." Neuron
The study of Bcl2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Vaux DL et al. (1988). "BCL2 and the regulation of programmed cell death." Journal of Cell Biology. PMID:3130979
- Cory S et al. (2003). "The BCL-2 family in cell death." Nature Reviews Cancer. PMID:12645241
- Ashkenazi A et al. (2017). "Targeting the BCL-2 family in cancer." Nature Reviews Cancer. PMID:29136194